Clinical Trial TitleInflammatory Bowel Disease (IBD) Drug Safety and Effectiveness Registry
National Clinical Trial Number:NCT03162549
Clinical Trial Protocol Description:
This is a long-term, observational study aiming to build a registry of patients with irritable bowel disease (IBD). The registry is designed to examine and compare the effectiveness and safety of treatments that are approved for use for treating IBD. In addition, this registry will also help to study IBD's epidemiology, natural history, and related comorbidities. A description of this clinical trial will be available at www.ClinicalTrials.gov, as required by U.S. law.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Are at least 18 years of age or older.
- Have a diagnosis of one of the following by a gastroenterologist: Crohn's disease or Ulcerative colitis.
- Are a prevalent user or new/incident user of an approved biologic drug or JAK inhibitor (Tofacitinib) for the treatment of Ulcerative colitis or Crohn's disease.
You will be excluded from the study if any of the following criteria apply to you:
- Are participating in or planning to participate in a clinical trial (Phase I - III) or a post-marketing study or registry (i.e. phase IV).
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.